Corey Clay, MD
Allergy & Immunology · Santa Fe, NMNPI 1417247727
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 553 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AstraZeneca at 27.8% of the total. 2025 is the largest year on record at $2,377, 2.6 times the $930 reported in 2019.
Across 553 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Regeneron Healthcare Solutions, Inc.$818
- CSL Behring$763
- Sanofi$521
- plus $3K from 28 others
What the payments were for
- Food & beverage$11,03398%
- Education$1752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 144 | $3,111 |
| GSK | 92 | $1,546 |
| Takeda Pharmaceuticals U.S.A., Inc. | 86 | $1,500 |
| Regeneron Healthcare Solutions, Inc. | 32 | $818 |
| CSL Behring | 33 | $763 |
| Sanofi | 22 | $521 |
| Grifols USA, LLC | 21 | $413 |
| Novartis | 19 | $372 |
| Incyte Corporation | 14 | $264 |
| Blueprint Medicines Corporation | 9 | $221 |
| Pharming Healthcare, Inc. | 8 | $220 |
| Genentech USA, Inc. | 6 | $151 |
| Boehringer Ingelheim | 7 | $129 |
| Stryker | 1 | $125 |
| AbbVie | 7 | $124 |
| Lilly USA, LLC | 5 | $96 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $94 |
| Amgen | 4 | $92 |
| Pfizer | 6 | $86 |
| Biocryst US Sales Co., LLC | 4 | $78 |
| Ionis Pharmaceuticals, Inc. | 2 | $65 |
| Optinose US, Inc. | 3 | $55 |
| Covis Pharma GmbH | 4 | $53 |
| Cycle Pharmaceuticals Inc | 2 | $46 |
| Merck | 3 | $43 |
| Shire North American Group Inc | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 3 | $36 |
| Tersera Therapeutics LLC | 2 | $35 |
| Bio Products Laboratory USA, Inc. | 3 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| ADMA Biomanufacturing LLC | 1 | $15 |
| Alk-abello, Inc | 1 | $14 |
| Kaleo, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 58 | $165,831 |
| Dupixent SyringeDupilumab | 23 | $81,851 |
| Dupixent PenDupilumab | 18 | $66,007 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 24 | $50,090 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 23 | $49,337 |
| Spiriva RespimatTiotropium Bromide | 39 | $20,008 |
| Epinephrine | 42 | $10,040 |
| Arnuity ElliptaFluticasone Furoate | 32 | $8,820 |
| Azelastine Hcl | 248 | $8,487 |
| Cromolyn Sodium | 11 | $7,744 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $7,385 |
| Qvar RedihalerBeclomethasone Dipropionate | 24 | $6,872 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $6,143 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $5,439 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $5,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,500 | $50,09024 claims |
| Grifols USA, LLCGamunex-C | $413 | $49,33723 claims |
| Boehringer IngelheimSpiriva Respimat | $129 | $20,00839 claims |
| GSKArnuity Ellipta | $1,546 | $8,82032 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $46 | $7,74411 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $36 | $6,87224 claims |
| AstraZenecaSymbicort | $3,111 | $4,21818 claims |
| MerckDulera | $43 | $4,02811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Santa Fe
- James SussmanSanta Fe$9K
- Janna TuckSanta Fe$4K
- Michael RuppLas Cruces$41K
- Amanda Grippen GoddardAlbuquerque$14K
- Jack GhablyAlbuquerque$14K
- Shanze WangAlbuquerque$12K
- Osman DokmeciAlbuquerque$12K
- Teresa Jenkins-MccordAlbuquerque$10K
- Todd FunkhouserLas Cruces$7K
- Steven TolberAlbuquerque$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.